Nivolumab for advanced cancer with autoimmune conditions
Treatments studied
Part of Blood & lymphatic, Bones, joints & muscles, Brain & nervous system, Cancer, Digestive system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old, and have advanced cancer (spread or not removable) or a cancer type/setting where PD-1/PD-L1 treatment is standard or approved
- Have an autoimmune disease that matches one of the study’s allowed types (such as dermatomyositis, scleroderma, rheumatoid arthritis, lupus, ulcerative colitis, Crohn’s, multiple sclerosis, Sjögren’s, psoriasis, or psoriatic arthritis)
- Have had no anti-PD-1 or anti-PD-L1 treatment before (for example, no prior nivolumab or similar drugs)
- Enough blood counts and organ function: blood tests must meet minimum levels (white cells, neutrophils, platelets) and liver/kidney tests must be within limits
- Be able to use birth control if you could become pregnant or father a child, and have a negative pregnancy test if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether adding ASTX727 to nivolumab can shrink relapsed or refractory B-cell lymphomas that have come back or did not respond to treatment. It also aims to find a safe dosing plan and see early signs of benefit in certain lymphoma types.
This trial tests a lower dose of nivolumab (an immunotherapy drug) given less frequently to treat cancers that have spread or cannot be surgically removed. The goal is to see if this approach works well while reducing side effects compared to standard dosing.
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
This trial studies nivolumab, an immune therapy, for skin squamous cell cancer that can’t be cured with surgery or radiation. It aims to see how well the treatment shrinks tumors and helps people live longer or longer without cancer growth.
This trial is testing a drug called Nivolumab (an immunotherapy) for people with rare solid tumors that have high levels of PD-L1. It might be an option if you have tried other treatments and they stopped working or caused too many side effects.
This trial tests whether adding the immunotherapy drug nivolumab to standard treatment works better for advanced stomach or esophageal cancer. It is for people whose cancer has already progressed after a first round of chemo plus immunotherapy.
Hear when a new Dermatomyositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.